news

Representatives Debbie Dingell (D-MI) and Eli Crane (R-AZ) today introduced a resolution expressing support for the Most-Favored-Nation drug pricing model, which would ensure Americans don’t pay more for the same prescription drugs than patients in other countries.

U.S. prices across all drugs, both brand name and generic, were nearly 2.78 times as high as prices in the comparison countries. Americans spend over $1,400 on prescription drugs every year—the highest per capita drug spending in the world.

In May, President Donald Trump signed an executive order instructing his Administration to take action to bring down the cost of U.S. drugs in line with other nations.

“In the wealthiest nation on earth, no one should have to choose between buying groceries and affording the medications they need to survive – and there’s absolutely no reason Americans should be spending more than any other country for the same prescriptions. America spends more on research than any other country, and for some reason, we still pay the most for these drugs,” Dingell said. “We need to bring down the cost of prescription drugs, and Most-Favored-Nation pricing would ensure that Americans have access to high-quality, affordable medications at the same cost as people overseas. This is a bipartisan, commonsense plan, and I hope to work with my colleagues on both sides of the aisle to make it a reality.”

"I’m grateful to co-lead this bipartisan resolution alongside Rep. Debbie Dingell,” Crane said. “For too long, Americans have paid the highest prescription drug prices in the world while subsidizing lower costs abroad. President Trump’s most-favored-nation executive order was a decisive step toward delivering relief to patients here at home. Congress must codify his effective policy, and our resolution is a critical step toward making that a reality."

View the full text of the resolution here.